{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:22:55Z","timestamp":1763810575057,"version":"3.41.2"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["667403"],"award-info":[{"award-number":["667403"]}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["289059","319243","322927","317680","310507","313267","326238","344698"],"award-info":[{"award-number":["289059","319243","322927","317680","310507","313267","326238","344698"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st","doi-asserted-by":"crossref","award":["2020026"],"award-info":[{"award-number":["2020026"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["716063"],"award-info":[{"award-number":["716063"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orion Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novo Nordisk Foundation Center for Stem Cell Biology","award":["NNF17CC0027852"],"award-info":[{"award-number":["NNF17CC0027852"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Each patient\u2019s cancer consists of multiple cell subpopulations that are inherently heterogeneous and may develop differing phenotypes such as drug sensitivity or resistance. A personalized treatment regimen should therefore target multiple oncoproteins in the cancer cell populations that are driving the treatment resistance or disease progression in a given patient to provide maximal therapeutic effect, while avoiding severe co-inhibition of non-malignant cells that would lead to toxic side effects. To address the intra- and inter-tumoral heterogeneity when designing combinatorial treatment regimens for cancer patients, we have implemented a machine learning-based platform to guide identification of safe and effective combinatorial treatments that selectively inhibit cancer-related dysfunctions or resistance mechanisms in individual patients. In this case study, we show how the platform enables prediction of cancer-selective drug combinations for patients with high-grade serous ovarian cancer using single-cell imaging cytometry drug response assay, combined with genome-wide transcriptomic and genetic profiles. The platform makes use of drug-target interaction networks to prioritize those combinations that warrant further preclinical testing in scarce patient-derived primary cells. During the case study in ovarian cancer patients, we investigated (i) the relative performance of various ensemble learning algorithms for drug response prediction, (ii) the use of matched single-cell RNA-sequencing data to deconvolute cell population-specific transcriptome profiles from bulk RNA-seq data, (iii) and whether multi-patient or patient-specific predictive models lead to better predictive accuracy. The general platform and the comparison results are expected to become useful for future studies that use similar predictive approaches also in other cancer types.<\/jats:p>","DOI":"10.1093\/bib\/bbab272","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T11:10:10Z","timestamp":1624705810000},"source":"Crossref","is-referenced-by-count":19,"title":["Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2112","authenticated-orcid":false,"given":"Liye","family":"He","sequence":"first","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland"}]},{"given":"Daria","family":"Bulanova","sequence":"additional","affiliation":[{"name":"Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen (UC), Helsinki, Finland"}]},{"given":"Jaana","family":"Oikkonen","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Antti","family":"H\u00e4kkinen","sequence":"additional","affiliation":[{"name":"University of Helsinki (UH), Helsinki, Finland"}]},{"given":"Kaiyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Shuyu","family":"Zheng","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Wenyu","family":"Wang","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Erdogan Pekcan","family":"Erkan","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Olli","family":"Carp\u00e9n","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH, Helsinki, Finland"}]},{"given":"Titta","family":"Joutsiniemi","sequence":"additional","affiliation":[{"name":"Gynecologic oncology in Turku University Hospital, Helsinki, Finland"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Program in UH and in University of Turku (UTU), Helsinki, Finland"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Programme in UH, Helsinki, Finland"}]},{"given":"Kaisa","family":"Huhtinen","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Programme in UH, Helsinki, Finland"}]},{"given":"Sampsa","family":"Hautaniemi","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Programme in UH, Helsinki, Finland"}]},{"given":"Anna","family":"V\u00e4h\u00e4rautio","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Programme in UH, Helsinki, Finland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-7710","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"ONCOSYS Research Programme in UH, Helsinki, Finland"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[{"name":"Biotech Research & Innovation Centre (BRIC), Helsinki, Finland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":false,"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[{"name":"FIMM and OCBE\/OUH, Helsinki, Finland"}]}],"member":"286","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"2021110815073473300_ref1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2021110815073473300_ref2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.drudis.2015.09.003","article-title":"Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives","volume":"21","author":"Bulusu","year":"2016","journal-title":"Drug Discov Today"},{"key":"2021110815073473300_ref3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nature Machine Intelligence"},{"key":"2021110815073473300_ref4","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1038\/s41467-019-09799-2","article-title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","volume":"10","author":"Menden","year":"2019","journal-title":"Nat Commun"},{"key":"2021110815073473300_ref5","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41467-020-19950-z","article-title":"Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects","volume":"11","author":"Julkunen","year":"2020","journal-title":"Nat Commun"},{"key":"2021110815073473300_ref6","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov Today"},{"key":"2021110815073473300_ref7","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"2021110815073473300_ref8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol Cell"},{"key":"2021110815073473300_ref9","article-title":"Multiobjective optimization identifies cancer-selective combination therapies","volume":"16","author":"Pulkkinen","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2021110815073473300_ref10","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/0008-5472.CAN-17-3644","article-title":"Patient-customized drug combination prediction and testing for T-cell Prolymphocytic leukemia patients","volume":"78","author":"He","year":"2018","journal-title":"Cancer Res"},{"key":"2021110815073473300_ref11","doi-asserted-by":"crossref","first-page":"12372","DOI":"10.1073\/pnas.1109363108","article-title":"Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer","volume":"108","author":"Cheung","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021110815073473300_ref12","first-page":"e595","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study, the lancet","volume":"4","author":"Snijder","year":"2017","journal-title":"Haematology"},{"key":"2021110815073473300_ref13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"2021110815073473300_ref14","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"2021110815073473300_ref15","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics (Oxford, England)"},{"key":"2021110815073473300_ref16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.chembiol.2017.11.009","article-title":"Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions","volume":"25","author":"Tang","year":"2018","journal-title":"Cell Chemical Biology"},{"key":"2021110815073473300_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab178","article-title":"PRISM: recovering cell type specific expression profiles from individual composite RNA-seq samples","author":"H\u00e4kkinen","year":"2021","journal-title":"Bioinformatics"},{"key":"2021110815073473300_ref18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"2021110815073473300_ref19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0167-9473(01)00065-2","article-title":"Stochastic gradient boosting","volume":"38","author":"Friedman","year":"2002","journal-title":"Comput Stat Data Anal"},{"key":"2021110815073473300_ref20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1214\/aos\/1013203451","article-title":"Greedy function approximation: a gradient boosting machine","volume":"29","author":"Friedman","year":"2001","journal-title":"Ann Stat"},{"key":"2021110815073473300_ref21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1145\/2939672.2939785","volume-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","author":"Chen","year":"2016"},{"key":"2021110815073473300_ref22","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gky1016","article-title":"CADD: predicting the deleteriousness of variants throughout the human genome","volume":"47","author":"Rentzsch","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2021110815073473300_ref23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.celrep.2013.08.028","article-title":"Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets","volume":"5","author":"Zaman","year":"2013","journal-title":"Cell Rep"},{"key":"2021110815073473300_ref24","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"2021110815073473300_ref25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"key":"2021110815073473300_ref26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","article-title":"Establishment of patient-derived tumor Xenograft models of epithelial ovarian Cancer for preclinical evaluation of novel therapeutics","volume":"23","author":"Liu","year":"2017","journal-title":"Clinical Cancer Res Off J Am Assoc Cancer Res"},{"key":"2021110815073473300_ref27","first-page":"19","article-title":"Machine learning approaches to drug response prediction: challenges and recent progress, NPJ precision","volume":"4","author":"Adam","year":"2020","journal-title":"Oncology"},{"key":"2021110815073473300_ref28","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1038\/s41467-020-19563-6","article-title":"Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action","volume":"11","author":"Ling","year":"2020","journal-title":"Nat Commun"},{"key":"2021110815073473300_ref29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","article-title":"Predicting drug response and synergy using a deep learning model of human cancer cells","volume":"38","author":"Kuenzi","year":"2020","journal-title":"Cancer Cell"},{"key":"2021110815073473300_ref30","doi-asserted-by":"crossref","first-page":"e1007803","DOI":"10.1371\/journal.pcbi.1007803","article-title":"Methodological challenges in translational drug response modeling in cancer: a systematic analysis with FORESEE","volume":"16","author":"Sch\u00e4tzle","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"2021110815073473300_ref31","first-page":"1","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","author":"Tanoli","year":"12 2021","journal-title":"Expert Opin Drug Discovery."},{"key":"2021110815073473300_ref32","doi-asserted-by":"crossref","first-page":"e9690","DOI":"10.15252\/msb.209690","article-title":"Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies","volume":"16","author":"Eduati","year":"2020","journal-title":"Mol Syst Biol"},{"key":"2021110815073473300_ref33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/annonc\/mdz104","article-title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","volume":"30","author":"Buechel","year":"2019","journal-title":"Ann Oncol"},{"key":"2021110815073473300_ref34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and new options in advanced epithelial ovarian Cancer treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2021110815073473300_ref35","doi-asserted-by":"crossref","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","article-title":"Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts","volume":"49","author":"Freshour","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2021110815073473300_ref36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23165-1","article-title":"Crowdsourced mapping of unexplored target space of kinase inhibitors","volume-title":"Nat Commun","author":"Cicho\u0144ska","year":"2021"},{"key":"2021110815073473300_ref37","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41467-017-01153-8","article-title":"Gene isoforms as expression-based biomarkers predictive of drug response in vitro","volume":"8","author":"Safikhani","year":"2017","journal-title":"Nat Commun"},{"key":"2021110815073473300_ref38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4038","article-title":"Patient-tailored design for selective co-inhibition of leukemic cell subpopulations","volume":"7","author":"Ianevski","year":"2021","journal-title":"Sci Adv"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab272\/41088658\/bbab272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab272\/41088658\/bbab272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T16:32:45Z","timestamp":1672590765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbab272\/6337896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbab272","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,8,3]]},"article-number":"bbab272"}}